SXTP VS INVO Stock Comparison

Performance

SXTP
10/100

SXTP returned -82.63% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

INVO
10/100

INVO returned -91.36% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Profit

SXTP
10/100

Out of the last 4 quarters, SXTP has had 0 profitable quarters and has increased their profits year over year on 0 of them.

INVO
10/100

Out of the last 20 quarters, INVO has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

SXTP
38/100

SXTP has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.

INVO
27/100

INVO has had a lower than average amount of volatility over the last 12 months giving it a score of 27 of 100.

Technicals

SXTP

"Technicals" not found for SXTP

INVO
71/100

INVO receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

Earnings

SXTP

"Earnings" not found for SXTP

INVO
10/100

INVO has missed earnings 7 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

60 Degrees Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / SXTP

Healthcare

Biotechnology

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

INVO BioScience,INC Common Stock Summary

Nasdaq / INVO

Healthcare

Medical - Devices

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Power up your portfolio